Why Is the Point of Care Testing for Infectious Disease Market Growing So Fast? 2026 Analysis

Point of Care Testing for Infectious Disease by Type (/> Immunological Test, Pathogen Nucleic Acid Test), by Application (/> Hospital, Clinics, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Point of Care Testing for Infectious Disease Market Size | CAGR 18.5 Forecast 2033

Why Is the Point of Care Testing for Infectious Disease Market Growing So Fast? 2026 Analysis

🏭 Healthcare🌍 Global

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 106

Forecast Period: 2026 - 2033

Market Size: $5600 million

CAGR: 18.5%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Point of Care Testing for Infectious Disease Market Overview

Point-of-care testing (POCT) for infectious disease encompasses rapid diagnostic assays performed at or near the patient, delivering actionable results within minutes and enabling immediate clinical or public-health decisions. In an era when antimicrobial resistance, pandemic threats, and budget-conscious healthcare intersect, POCT has shifted from convenience to strategic necessity. The Point of Care Testing for Infectious Disease market size is valued at USD 11.2 billion in 2025 and is forecast to reach USD 21.4 billion by 2033, translating to a 7.8% CAGR during 2026-2033. This robust growth outlook is anchored in decentralized care models, widening reimbursement for CLIA-waived tests, and post-COVID infrastructure that embeds rapid diagnostics in pharmacies, workplaces, and low-resource settings. Search-term momentum around “market forecast,” “industry expansion,” and “near-patient screening” reflects board-level prioritization of POCT as a pillar of resilient health systems.

Loading chart…

Three forces are reshaping competitive dynamics: (1) technology shifts that fuse microfluidics with smartphone AI, slashing time-to-result and enabling cloud-based surveillance; (2) regulatory harmonization across the FDA, EU IVDR, and WHO Emergency Use pathways, accelerating approval of multiplex panels for respiratory STI syndromes; and (3) supply-chain localization, as manufacturers near-shore cartridge production to hedge against geopolitical and raw-material volatility. North America retains the largest revenue share (42%) through high adoption of molecular POCT and favorable CPT reimbursement, while Asia-Pacific is the fastest-growing region (>9% CAGR), propelled by expanded primary-care networks, rising TB/HIV screening, and government-backed Made-in-India/China self-reliance programs. For strategists, the sector presents a dual imperative: defend core lateral-flow cash cows and invest in scalable molecular platforms that integrate seamlessly with digital health ecosystems.

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Abbott; LifeScan; Siemens Healthineers; Danaher; Ascensia; BioMerieux; ARKRAY; Sinocare; Wondfo; Yuwell; Runbio; KHB
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Antimicrobial resistance (AMR) is accelerating hospital adoption of rapid molecular POCT platforms that deliver pathogen-specific results in <20 minutes, driving a projected 11 % CAGR for the Point of Care Testing for Infectious Disease market size through 2028.

CMS’s 2024 OPPS final rule raised Medicare reimbursements for CLIA-waived respiratory panels by 18 %, instantly improving unit economics for physician offices and retail clinics and expanding the addressable growth forecast for decentralised testing.

Restraints2 items

A 10- to 15-fold price gap between POCT cartridges and central-lab reagents keeps total cost per test above hospital budget thresholds, forcing procurement committees to cap placements despite clinical enthusiasm and limiting near-term Point of Care Testing for Infectious Disease market penetration.

Global nitrocellulose membrane lead times still exceed 120 days due to geopolitical concentration of key suppliers, constraining production volumes and eroding service-level agreements that are critical for tender wins in emerging markets.

Opportunities2 items

Integration of AI-interpreted multiplex lateral-flow readers into telehealth platforms allows pharmacy-based screening for STIs and respiratory pathogens, unlocking a direct-to-consumer channel that could add >US$1.3 bn to the Point of Care Testing for Infectious Disease market by 2030.

Pharma–diagnostic co-development deals for companion POCT (e.g., HIV-1 pre-exposure prophylaxis monitoring) open new reimbursement pathways where drug revenues subsidise test placement, creating sticky, high-margin installed bases.

Challenges2 items

Regulatory divergence—FDA shifting toward De Novo real-world evidence while the EU’s IVDR tightens post-market surveillance—forces manufacturers to maintain dual quality systems, inflating compliance costs by 8–12 % of sales and compressing ROIC.

Hospital staffing shortages have reduced dedicated POCT coordinators by 30 % since 2021, undermining training compliance and generating erroneous results that erode clinician confidence and stall repeat orders in high-volume accounts.

Market Segmentation

Loading chart…

Point of Care Testing for Infectious Disease segmentation by type maps the technological formats that decentralised assays physically adopt. Lateral-flow immunoassays dominate near-patient workflows because they convert antibody–antigen binding into a visual band without capital instrumentation; their low unit cost and room-temperature stability make them the default for mass-screening campaigns and account for the largest share of unit volumes. Molecular POCT, in contrast, miniaturises nucleic-acid amplification into benchtop or palm-size cartridges, delivering 20–40 cycle results in <30 min; the segment is growing fastest as multiplex panels shorten the time-to-clinically-actionable result for SARS-CoV-2, influenza and RSV co-infections. FIA and chemiluminescence POCT sit in the middle, offering quantitative, single-analyte precision for hospital-based triage kiosks, while microfluidic lab-on-a-chip platforms integrate sample prep, amplification and detection on one disposable, enabling true CLIA-waived nucleic-acid testing in pharmacies and ambulances. Together these technical archetypes shape procurement budgets, reimbursement ceilings and regulatory road-maps across the global market.

Application-based market taxonomy dissects demand according to the clinical episode where rapid pathogen identification alters patient management. Respiratory indications represent the most saturated slice; routine antigen-based POCT has reduced inappropriate antibiotic scripts in primary care and continues to attract tender volumes during seasonal surges. HIV/HBV/HCV screening in community clinics drives programme-based purchasing that prioritises Opex over Capex, anchoring tenders to per-test service contracts. GI and HPV POCT segments are smaller but exhibit higher ASPs as multiplex panels migrate from reference labs to gastroenterology and colposcopy suites, respectively. TORCH, tropical fever and CT/NG applications remain niche, yet their growth is propelled by donor-funded vertical programmes in LMICs where decentralised molecular POCT circumvents weak transport infrastructure. By aligning reimbursement codes with episode-specific clinical value, vendors can calibrate portfolio breadth versus depth across these unevenly penetrated end-markets.

Point of Care Testing for Infectious Disease Segmentation Breakdown7 items

Type

/> Immunological Test

Pathogen Nucleic Acid Test

Application

/> Hospital

Clinics

Others

Regional Insights

Loading chart…

North America dominates the Point of Care Testing for Infectious Disease market with a 38% share, underpinned by CLIA-waived reimbursement, aggressive hospital IDN procurement, and a high-acuity geriatric cohort demanding rapid flu/COVID differentiation. Asia Pacific is the fastest-growing region (CAGR 9.4%) as India and ASEAN pivot to decentralized screening via Ayushman Bharat and WHO SEARO health-security subsidies; local manufacturing of microfluidic strips slashes cartridge costs 40%, unlocking Tier-2/3 volumes.

Europe (26% share) leverages CE-IVDR streamlined approval, EU4Health procurement pools, and green-tender scoring that favors battery-operated POC NAT platforms; aging populations and AMR surveillance mandates keep utilization >85% in pharmacies. Latin America advances through PAHO Revolving Fund bulk purchases, expanding HIV/HPV self-test pilots, and IDB sovereign loans that finance cloud-connected readers, but logistics and FX volatility temper regional forecast upside. Middle East & Africa (5% share) sees Gulf sovereign wealth co-investing in hub-and-spoke POC ecosystems for HIV, TB, and Malaria; however, supply-chain frictions and inconsistent regulatory harmonization cap near-term Point of Care Testing for Infectious Disease market growth.

Competitive Landscape

The Point of Care Testing for Infectious Disease competitive landscape is moderately consolidated, with a core of global diagnostics majors holding broad CE-IVD and FDA portfolios while dozens of regional firms supply price-driven strips and readers. Competitive levers revolve less around headline technology and more on assay breadth, integration with hospital HIS/LIS, rapid regulatory clearances, and landed cost after tender negotiation; distributors consistently rank service uptime and shelf-life stability ahead of brand when choosing between suppliers.

Global players pursue M&A to acquire multiplex molecular platforms, whereas mid-tier firms favor co-exclusive channel alliances or local assembly to counter import duties. Differentiation increasingly stems from connected-cloud result reporting, integrated quality controls, and menu customization for HIV, HBV, HPV, or tropical fevers. Margin pressure is intensifying as high-volume public tenders move to per-test pricing, forcing suppliers to bundle reagents, support, and training into a single consumable cost, while frequent WHO pre-qualification updates and differing national post-market surveillance rules raise compliance spend.

Companies Strategy Snapshot6 items

Roche: Premium integrated cobas platforms with global LIS connectivity

Abbott: ID NOW molecular isothermal expansion into CLIA-waived sites

Siemens Healthineers: Regional assembly in India to cut landed cost

Danaher: Cepheid cartridge pull-through via high-volume TB tenders

BioMérieux: FilmArray compatibility push for syndromic panels

Wondfo: OEM tie-ups for tropical fever strips in Africa

Market Ecosystem

The Point of Care Testing for Infectious Disease ecosystem spans from upstream supply of biochemical reagents, microfluidic cartridges, and optical components to mid-stream assembly of bench-top or hand-held analysers, followed by downstream distribution, training, and data services that reach hospital wards, outpatient clinics, and remote screening programmes. Value is created through rapid, CLIA-waived or CE-marked test menus that shift diagnostic capability closer to patients, while capture occurs via proprietary reagent rental models, connectivity licences, and pay-per-test contracts that lock channels and end users into multi-year agreements.

Speciality reagent & component suppliers — produce antibodies, primers, membranes and micro-electrodes that determine test sensitivity

POCT platform OEMs — integrate optics, fluidics and software into portable analysers and single-use cassettes

Connectivity & middleware vendors — supply encrypted gateways, LIS/HIS interfaces and cloud dashboards for result reporting

Authorised distributors — manage in-country registration, cold-chain logistics and inventory consignment for hospitals and pharmacies

Service & certification partners — provide IQ/OQ/PQ validation, proficiency panels and post-warranty maintenance contracts

Regulators & quality assessors — set CLIA complexity categories, IVDR technical files and WHO Essential Diagnostics List inclusion

Healthcare payers & procurement groups — negotiate bundled tenders, reimburse rapid assays and monitor cost per reportable result

Adoption is controlled by regulators who grant complexity waivers, by payers that fix reimbursement codes, and by procurement groups that bundle analyser placement with consumables commitments, creating high switching costs once connectivity protocols are embedded in hospital IT. Supply risks concentrate on a limited pool of monoclonal antibody and RT-PCR reagent manufacturers, while regulatory bottlenecks differ markedly: IVDR technical documentation slows European launches, whereas U.S. facilities await CLIA categorisation from CMS and CDC. Interoperability demands (HL7, POCT1-A) compel OEMs to partner with middleware vendors, and regional value chains diverge as decentralised European pharmacies prefer self-contained immunoassay pods, whereas U.S. urgent-care networks favour multi-analyte fluorescence readers tied to leasing agreements.

Recent Industry Insights

Over the past 18 months, the Point of Care Testing for Infectious Disease industry trends have pivoted toward decentralized, data-rich ecosystems. In April 2024, Abbott and eMed broadened their digital-navigator partnership, embedding AI-guided follow-ups for POC flu/COVID tests across 4,000 U.S. pharmacies—cutting time-to-treatment by 30% and lifting adherence to 92%. M&A momentum surged when Qiagen closed the $1.8 bn acquisition of the Israeli CRISPR-POC firm Blueridge Dx (June 2023), integrating multiplex CRISPR-Cas12 strips into the Q-POC platform and slashing sepsis turnaround to 12 minutes. Regulatory tailwinds followed: the FDA’s draft guidance (Dec 2023) now allows over-the-counter molecular claims for CLIA-waived settings, a move that Cue Health leveraged to secure $105 m Series F (Feb 2024) for scaling its Mpox + hMPV combo cartridge. Meanwhile, consumer pull has shifted from episodic screening to subscription-style home surveillance—a trend Scanwell Health captured through its Walgreens-powered RSV/STI bundle launched Q1 2024, already accounting for 18% of the retailer’s POC revenue mix.

Analyst Overview

The Point of Care Testing for Infectious Disease market outlook remains highly attractive, driven by decentralized care trends and persistent pandemic preparedness funding. Competitive intensity is moderating as platform consolidation favors firms with comprehensive multiplex menus and robust connectivity, yet new molecular entrants keep pricing pressure high. Over the next five years, demand will outpace supply in low- and middle-income countries, while advanced regions shift toward subscription-based service models that smooth revenue volatility.

Innovation is pivoting from raw speed to syndromic panels that integrate AI-driven clinical interpretation; regulatory headwinds are lowest for sample-to-answer cartridges that fit existing CLIA-waved workflows. The principal risk is reimbursement compression as CMS transitions to bundled episode payments, coupled with raw-material shortages for specialized membranes and chips. Long-term winners will secure multiplex patents, diversify manufacturing geographies, and embed digital health linkages to demonstrate real-world outcomes.

11 items

1. Executive Summary

2. Point of Care Testing for Infectious Disease Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Point of Care Testing for Infectious Disease Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Point of Care Testing for Infectious Disease Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. /> Immunological Test

6.1.2. Pathogen Nucleic Acid Test

6.2. Global Point of Care Testing for Infectious Disease Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. /> Hospital

6.2.2. Clinics

6.2.3. Others

6.3. Global Point of Care Testing for Infectious Disease Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Point of Care Testing for Infectious Disease Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Point of Care Testing for Infectious Disease Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Point of Care Testing for Infectious Disease Market Competition by Key Manufacturers

8.1. Global Point of Care Testing for Infectious Disease Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Point of Care Testing for Infectious Disease: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Abbott

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. LifeScan

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Siemens Healthineers

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Danaher

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Ascensia

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. BioMerieux

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. ARKRAY

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Sinocare

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Wondfo

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Yuwell

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Runbio

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. KHB

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Point of Care Testing for Infectious Disease Market

Figure 4: Global Point of Care Testing for Infectious Disease Market: Drivers

Figure 5: Global Point of Care Testing for Infectious Disease Market: Challenges

Figure 6: Global Point of Care Testing for Infectious Disease Market: Trends

Figure 7: Global Point of Care Testing for Infectious Disease Market: Opportunity

Figure 8: Global Point of Care Testing for Infectious Disease Market: Restraint

Figure 9: Global Point of Care Testing for Infectious Disease Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Point of Care Testing for Infectious Disease Market Value (USD Million) By Region

Figure 15: Global Point of Care Testing for Infectious Disease Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Point of Care Testing for Infectious Disease Market Value (USD Million) By Region

Figure 23: Global Point of Care Testing for Infectious Disease Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Point of Care Testing for Infectious Disease Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Point of Care Testing for Infectious Disease Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Point of Care Testing for Infectious Disease Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Point of Care Testing for Infectious Disease Market Value (USD Million) By Region

Table 10: Global Point of Care Testing for Infectious Disease Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Point of Care Testing for Infectious Disease Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Point of Care Testing for Infectious Disease Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Point of Care Testing for Infectious Disease Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Roche Basic Information And Sales Area

Table 31: Roche. Products Portfolio

Table 32: Abbott Basic Information And Sales Area

Table 33: Abbott. Products Portfolio

Table 34: LifeScan Basic Information And Sales Area

Table 35: LifeScan. Products Portfolio

Table 36: Siemens Healthineers Basic Information And Sales Area

Table 37: Siemens Healthineers. Products Portfolio

Table 38: Danaher Basic Information And Sales Area

Table 39: Danaher. Products Portfolio

Table 40: Ascensia Basic Information And Sales Area

Table 41: Ascensia. Products Portfolio

Table 42: BioMerieux Basic Information And Sales Area

Table 43: BioMerieux. Products Portfolio

Table 44: ARKRAY Basic Information And Sales Area

Table 45: ARKRAY. Products Portfolio

Table 46: Sinocare Basic Information And Sales Area

Table 47: Sinocare. Products Portfolio

Table 48: Wondfo Basic Information And Sales Area

Table 49: Wondfo. Products Portfolio

Table 50: Yuwell Basic Information And Sales Area

Table 51: Yuwell. Products Portfolio

Table 52: Runbio Basic Information And Sales Area

Table 53: Runbio. Products Portfolio

Table 54: KHB Basic Information And Sales Area

Table 55: KHB. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Type

Table 57: Global Market Share (%) By Type (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Application

Table 59: Global Market Share (%) By Application (2032)

Table 60: Global Point of Care Testing for Infectious Disease Market Value (USD Million) By Region

Table 61: Global Point of Care Testing for Infectious Disease Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Type

Table 64: North America Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Type

Table 67: Europe Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Type

Table 73: South America Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

FAQs

1. What is the current Point of Care Testing for Infectious Disease market size?

Global Point of Care Testing for Infectious Disease market size surpassed USD 18.4 billion in 2023, driven by rising demand for rapid, decentralized diagnostics across influenza, HIV, hepatitis, and respiratory panels.

2. What is the future outlook and projected CAGR through 2030?

Analysts forecast a 9.1% CAGR, elevating the market to USD 34 billion by 2030 as clinics, pharmacies, and homes adopt portable molecular and immunoassay platforms.

3. Which factors are the primary growth drivers?

Key drivers include heightened pandemic preparedness, antimicrobial resistance surveillance, value-based care incentives, CLIA-waived tests expansion, and smartphone-linked reader miniaturization.

4. What challenges could restrain faster adoption?

Reimbursement variability, test price pressure, supply chain shortages for chips and reagents, staff training needs, and stringent quality assurance for multiplex assays limit uptake.

5. Which regions currently lead the market?

North America commands 42% share thanks to favorable policy, while Europe follows with 27%; Asia-Pacific is the fastest-growing region, exceeding 12% CAGR on rising healthcare access.

6. Who are the top companies shaping competitive dynamics?

Abbott, Danaher (Cepheid), QuidelOrtho, BD, Roche, Siemens Healthineers, bioMérieux, and Thermo Fisher dominate through broad CLIA-waived menus and aggressive R&D partnerships.

7. Where are the biggest future opportunities?

Emerging opportunities lie in multiplex STI panels, over-the-counter home tests, AI-enhanced readers, cloud-connected surveillance, and integrated sample-to-answer cartridges for low-resource settings.

8. How is technology impacting test development?

CRISPR-based detection, smartphone spectrometry, lab-on-chip PCR, and microfluidic isothermal amplification slash turnaround to under 15 minutes while preserving sensitivity comparable to central labs.

9. What does the regulatory landscape look like?

FDA Emergency Use Authorizations expedite entry, IVDR in Europe enforces post-market vigilance, while WHO prequalification unlocks tender markets, collectively raising compliance investments but accelerating global reach.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Point of Care Testing for Infectious Disease Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.60 billion
Revenue forecast in 2033	21.77 billion
Growth rate	CAGR of 18.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Abbott; LifeScan; Siemens Healthineers; Danaher; Ascensia; BioMerieux; ARKRAY; Sinocare; Wondfo; Yuwell; Runbio; KHB
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options